Works about ROSIGLITAZONE

Results: 702

Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.

Published in:

Liver International, 2013, v. 33, n. 4, p. 624, doi. 10.1111/liv.12100

By:

Skoien, Richard;
Richardson, Michelle M.;
Jonsson, Julie R.;
Powell, Elizabeth E.;
Brunt, Elizabeth M.;
Neuschwander‐Tetri, Brent A.;
Bhathal, Prithi S.;
Dixon, John B.;
O'Brien, Paul E.;
Tilg, Herbert;
Moschen, Alexander R.;
Baumann, Ulrich;
Brown, Rachel M.;
Couper, Richard T.;
Manton, Nicholas D.;
Ee, Looi C.;
Weltman, Martin;
Clouston, Andrew D.

Publication type:

Article

Inverse association of PPARγ agonists use and high grade glioma development.

Published in:

Journal of Neuro-Oncology, 2010, v. 100, n. 2, p. 233, doi. 10.1007/s11060-010-0185-x

By:

Grommes, Christian;
Conway, Devon;
Alshekhlee, Amer;
Barnholtz-Sloan, Jill

Publication type:

Article

Structured Supports and Catalysts: Design, Preparation, and Applications.

Published in:

2022

By:

Martino, Marco

Publication type:

Editorial

Synthesis of Thiazolidinedione Compound Library.

Published in:

Compounds, 2022, v. 2, n. 3, p. 182, doi. 10.3390/compounds2030013

By:

Damkaci, Fehmi;
Szymaniak, Adam A.;
Biasini, Jason P.;
Cotroneo, Ryan

Publication type:

Article

Development and in vitro evaluation of floating rosiglitazone maleate microspheres.

Published in:

Drug Development & Industrial Pharmacy, 2009, v. 35, n. 7, p. 834, doi. 10.1080/03639040802627421

By:

Rao, M.R.P.;
Borate, S.G.;
Thanki, K.C.;
Ranpise, A.A.;
Parikh, G.N.

Publication type:

Article

Induction of peroxisomal proliferator-activated receptor γ and peroxisomal proliferator-activated receptor γ coactivator 1 by unsaturated fatty acids, retinoic acid, and carotenoids in preadipocytes obtained from bovine white adipose tissue<sup>1,2</sup>

Published in:

Journal of Animal Science, 2010, v. 88, n. 5, p. 1801, doi. 10.2527/jas.2009-2579

By:

Garcia-Rojas, P.;
Antaramian, A.;
González-Dávalos, L.;
Villarroya, F.;
Shimada, A.;
Varela-EchavarrIa, A.;
Moral, 0.

Publication type:

Article

Determination of Rosiglitazone by Direct Analysis in Real-Time Mass Spectrometry.

Published in:

Analytical Letters, 2017, v. 50, n. 11, p. 1721, doi. 10.1080/00032719.2016.1248245

By:

Liu, Wenlong;
He, Yangfang;
Zhang, Hongmei;
Su, Rui;
Xiu, Yang;
Liu, Shuying

Publication type:

Article

Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.

Published in:

Journal of Diabetes Research, 2018, p. 1, doi. 10.1155/2018/4627842

By:

Li, Jia;
Xue, Yao-Ming;
Zhu, Bo;
Pan, Yong-Hua;
Zhang, Yan;
Wang, Chunxia;
Li, Yuhao

Publication type:

Article

Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 143, doi. 10.1002/cpdd.150

By:

Braeckman, Rene A.;
Stirtan, William G.;
Soni, Paresh N.

Publication type:

Article

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.

Published in:

Clinical Pharmacology in Drug Development, 2015, v. 4, n. 1, p. 56, doi. 10.1002/cpdd.133

By:

Kosoglou, Teddy;
Kumar, Bharath;
Statkevich, Paul;
Schiller, James E.;
Kantesaria, Bhavna;
Hanson, Mary E.;
Sisk, Christine McCrary;
Cutler, David L.

Publication type:

Article

High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells.

Published in:

Frontiers in Pharmacology, 2017, p. 1, doi. 10.3389/fphar.2017.00772

By:

Rondón-Ortiz, Alejandro N.;
Lino Cardenas, Christian L.;
Martínez-Málaga, Jimena;
Gonzales-Urday, Ana L.;
Gugnani, Kuljeet S.;
Böhlke, Mark;
Maher, Timothy J.;
Pino-Figueroa, Alejandro J.

Publication type:

Article

Rosiglitazone May Assist With Glycemic Control in the ICU.

Published in:

Journal of Intensive Care Medicine, 2010, v. 25, n. 2, p. 117, doi. 10.1177/0885066609355264

By:

Lissauer, Matthew;
Feild, Carinda;
Fasanmi, Foyin;
Johnson, Steven B.

Publication type:

Article

Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1‐year randomized study.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 7, p. 1740, doi. 10.1111/dom.13293

By:

Piché, Marie‐eve;
Laberge, Anne‐sophie;
Brassard, Patrice;
Arsenault, Benoit J.;
Bertrand, Olivier F.;
Després, Jean‐pierre;
Costerousse, Olivier;
Poirier, Paul

Publication type:

Article

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial.

Published in:

Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 949, doi. 10.1111/dom.12487

By:

Florez, H.;
Reaven, P. D.;
Bahn, G.;
Moritz, T.;
Warren, S.;
Marks, J.;
Reda, D.;
Duckworth, W.;
Abraira, C.;
Hayward, R.;
Emanuele, N.

Publication type:

Article

Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.

Published in:

Diabetes, Obesity & Metabolism, 2015, v. 17, n. 4, p. 335, doi. 10.1111/dom.12380

By:

Fisher, M.

Publication type:

Article

APOE* 3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.

Published in:

Diabetes, Obesity & Metabolism, 2014, v. 16, n. 6, p. 537, doi. 10.1111/dom.12252

By:

van den Hoek, A. M.;
van der Hoorn, J. W. A.;
Maas, A. C.;
van den Hoogen, R. M.;
van Nieuwkoop, A.;
Droog, S.;
Offerman, E. H.;
Pieterman, E. J.;
Havekes, L. M.;
Princen, H. M. G.

Publication type:

Article

Observational follow-up of the PROactive study: a 6-year update.

Published in:

Diabetes, Obesity & Metabolism, 2014, v. 16, n. 1, p. 63, doi. 10.1111/dom.12180

By:

Erdmann, E.;
Song, E.;
Spanheimer, R.;
van Troostenburg de Bruyn, A.‐R.;
Perez, A.

Publication type:

Article

Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

Published in:

Diabetes, Obesity & Metabolism, 2013, v. 15, n. 11, p. 967, doi. 10.1111/dom.12101

By:

Consoli, A.;
Formoso, G.

Publication type:

Article

News and Views.

Published in:

Diabetes, Obesity & Metabolism, 2012, v. 14, n. 7, p. 673, doi. 10.1111/j.1463-1326.2012.01621.x

By:

Idris, Iskandar

Publication type:

Article

The design of the liraglutide clinical trial programme.

Published in:

Diabetes, Obesity & Metabolism, 2012, v. 14, p. 4, doi. 10.1111/j.1463-1326.2012.01573.x

By:

Nauck, M. A.

Publication type:

Article

Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.

Published in:

Diabetes, Obesity & Metabolism, 2012, v. 14, n. 2, p. 181, doi. 10.1111/j.1463-1326.2011.01510.x

By:

Lazich, I.;
Sarafidis, P.;
de Guzman, E.;
Patel, A.;
Oliva, R.;
Bakris, G.

Publication type:

Article

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-na ïve type 2 diabetes mellitus patients

Published in:

Diabetes, Obesity & Metabolism, 2011, v. 13, n. 11, p. 1036, doi. 10.1111/j.1463-1326.2011.01461.x

By:

Borges, J. L. C.;
Bilezikian, J. P.;
Jones-Leone, A. R.;
Acusta, A. P.;
Ambery, P. D.;
Nino, A. J.;
Grosse, M.;
Fitzpatrick, L. A.;
Cobitz, A. R.

Publication type:

Article

Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 12, p. 1023, doi. 10.1111/j.1463-1326.2010.01262.x

By:

Schernthaner, G.;
Chilton, R. J.

Publication type:

Article

News and Views.

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 11, p. 1019, doi. 10.1111/j.1463-1326.2010.01310.x

By:

Idris, Iskandar

Publication type:

Article

Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes.

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 9, p. 825, doi. 10.1111/j.1463-1326.2010.01234.x

By:

Desch, S.;
Sonnabend, M.;
Niebauer, J.;
Sixt, S.;
Sareban, M.;
Eitel, I.;
de Waha, S.;
Thiele, H.;
Blüher, M.;
Schuler, G.

Publication type:

Article

Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 9, p. 806, doi. 10.1111/j.1463-1326.2010.01237.x

By:

Rabøl, R.;
Boushel, R.;
Almdal, T.;
Hansen, C. N.;
Ploug, T.;
Haugaard, S. B.;
Prats, C.;
Madsbad, S.;
Dela, F.

Publication type:

Article

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 8, p. 716, doi. 10.1111/j.1463-1326.2010.01225.x

By:

Aubert, R. E.;
Herrera, V.;
Chen, W.;
Haffner, S. M.;
Pendergrass, M.

Publication type:

Article

Selective effects of PPARγ agonists and antagonists on human pre-adipocyte differentiation.

Published in:

Diabetes, Obesity & Metabolism, 2010, v. 12, n. 3, p. 195, doi. 10.1111/j.1463-1326.2009.01149.x

By:

Leyvraz, C.;
Suter, M.;
Verdumo, C.;
Calmes, J.-M.;
Paroz, A.;
Darimont, C.;
Gaillard, R. C.;
Pralong, F. P.;
Giusti, V.

Publication type:

Article

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2009, v. 11, n. 12, p. 1091, doi. 10.1111/j.1463-1326.2009.01087.x

By:

Derosa, G.;
Tinelli, C.;
Maffioli, P.

Publication type:

Article

Theabrownin from Pu-erh tea together with swinging exercise synergistically ameliorates obesity and insulin resistance in rats.

Published in:

European Journal of Nutrition, 2020, v. 59, n. 5, p. 1937, doi. 10.1007/s00394-019-02044-y

By:

Wu, Enkai;
Zhang, Tingting;
Tan, Chao;
Peng, Chunxiu;
Chisti, Yusuf;
Wang, Qiuping;
Gong, Jiashun

Publication type:

Article

Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

Published in:

2016

By:

Yeh, James;
Sarpatwari, Ameet;
Kesselheim, Aaron;
Yeh, James S;
Kesselheim, Aaron S

Publication type:

journal article

Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia.

Published in:

Drug Safety, 2014, v. 37, n. 1, p. 53, doi. 10.1007/s40264-013-0124-9

By:

A.Wahab, Izyan;
Pratt, Nicole;
Kalisch, Lisa;
Roughead, Elizabeth

Publication type:

Article

Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study.

Published in:

Drug Safety, 2013, v. 36, n. 8, p. 643, doi. 10.1007/s40264-013-0080-4

By:

Hsiao, Fei-Yuan;
Hsieh, Pei-Hua;
Huang, Weng-Foung;
Tsai, Yi-Wen;
Gau, Churn-Shiouh

Publication type:

Article

Formulation and evaluation of floating tablet of rosiglitazone malate.

Published in:

International Journal of Pharmacy & Life Sciences, 2012, v. 3, n. 2, p. 1475

By:

Singh, Koushlendra;
Dhakar, Virendra Kumar;
Rai, Vishnu Kant

Publication type:

Article

PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation.

Published in:

Molecular Medicine Reports, 2018, v. 18, n. 3, p. 3421, doi. 10.3892/mmr.2018.9311

By:

Wang, Wen-Da;
Sun, Rui;
Chen, Yue-Xin

Publication type:

Article

PPAR-γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution-induced damage.

Published in:

Molecular Medicine Reports, 2017, v. 15, n. 4, p. 1786, doi. 10.3892/mmr.2017.6196

By:

YUN-FANG ZHANG;
QI WANG;
YAN-YAN SU;
JIE-LIN WANG;
BAO-JUN HUA;
SHEN YANG;
JUN-XIA FENG;
HONG-YAN LI

Publication type:

Article

Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression.

Published in:

Molecular Medicine Reports, 2014, v. 10, n. 4, p. 2137, doi. 10.3892/mmr.2014.2407

By:

MINGZHONG RUI;
ZHANPING HUANG;
YING LIU;
ZIYAN WANG;
RUI LIU;
JINXIANG FU;
HAIWEN HUANG

Publication type:

Article

Peroxisome proliferator-activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.

Published in:

Molecular Medicine Reports, 2014, v. 10, n. 2, p. 695, doi. 10.3892/mmr.2014.2232

By:

LIANG QIN;
CHEN GONG;
AN-MIN CHEN;
FENG-JING GUO;
FEI XU;
YE REN;
HUI LIAO

Publication type:

Article

Peroxisome proliferator-activated receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway.

Published in:

Molecular Medicine Reports, 2014, v. 10, n. 1, p. 276, doi. 10.3892/mmr.2014.2198

By:

LIANG QIN;
YE REN;
AN-MIN CHEN;
FENG-JING GUO;
FEI XU;
CHEN GONG;
PENG CHENG;
YU DU;
HUI LIAO

Publication type:

Article

Rosiglitazone alleviates injury in rats with adenine-induced chronic kidney disease.

Published in:

Molecular Medicine Reports, 2013, v. 8, n. 6, p. 1831, doi. 10.3892/mmr.2013.1715

By:

YING HUANG;
YAN LEI;
ZHIHUA ZHENG;
XIAOHUA WANG;
MINGLIANG HU;
RONGJUN LIU;
XUEQING YU

Publication type:

Article

Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study.

Published in:

Diabetology & Metabolic Syndrome, 2016, v. 4, p. 1, doi. 10.1186/s13098-015-0120-6

By:

Ulhôa Tostes, Glauce Cordeiro;
Rosário Cunha, Maria;
Rosa Tsumeshiro Fukui;
Silva Correia, Márcia Regina;
Rocha, Dalva Marreiro;
dos Santos, Rosa Ferreira;
da Silva, Maria Elizabeth Rossi

Publication type:

Article

Rosiglitazone induces hepatocyte injury by increasing DCA accumulation through OATP1A4 inhibiting in mice.

Published in:

Arabian Journal of Chemistry, 2023, v. 16, n. 10, p. N.PAG, doi. 10.1016/j.arabjc.2023.105142

By:

Tan, Daopeng;
Ling, Lei;
Qin, Lin;
Lu, Yanliu;
Wu, Di;
He, Yuqi

Publication type:

Article

How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD.

Published in:

Methodist DeBakey Cardiovascular Journal, 2022, v. 18, n. 5, p. 54, doi. 10.14797/mdcvj.1181

By:

NISSEN, STEVEN E.;
YOUNG, JAMES B.

Publication type:

Article

All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.

Published in:

European Journal of Haematology, 2009, v. 83, n. 3, p. 191, doi. 10.1111/j.1600-0609.2009.01277.x

By:

Huang, Haiwen;
Wu, Depei;
Fu, Jinxiang;
Chen, Guanghua;
Chang, Weirong;
Chow, Howard C. H.;
Leung, Anskar Y. H.;
Liang, Raymond

Publication type:

Article

Rosiglitazone Attenuates Atrial Structural Remodeling and Atrial Fibrillation Promotion in Alloxan-Induced Diabetic Rabbits.

Published in:

Cardiovascular Therapeutics, 2014, v. 32, n. 4, p. 178, doi. 10.1111/1755-5922.12079

By:

Liu, Tong;
Zhao, Hui;
Li, Jian;
Korantzopoulos, Panagiotis;
Li, Guangping

Publication type:

Article

Effects of Laropiprant, a Selective Prostaglandin D<sub>2</sub> Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone.

Published in:

Cardiovascular Therapeutics, 2009, v. 27, n. 4, p. 239, doi. 10.1111/j.1755-5922.2009.00104.x

By:

Schwartz, Jules I.;
Stroh, Mark;
Bing Gao;
Fang Liu;
Rosko, Kimberly;
Zajic, Stefan;
Meehan, Alan J.;
Ruckle, Jon;
Eseng Lai;
Wagner, John A.

Publication type:

Article

Effect of rosiglitazone on the risk for myocardial infarction and death from cardiovascular causes.

Published in:: Einstein (16794508), 2009, v. 7, n. 1, p. 24
Publication type:: Article

Multiple gene-drug prediction tool reveals Rosiglitazone based treatment pathway for non-segmental vitiligo.

Published in:

Inflammation, 2024, v. 47, n. 2, p. 678, doi. 10.1007/s10753-023-01937-9

By:

Zhao, Sijia;
Chen, Xi;
Dutta, Kuheli;
Chen, Jia;
Wang, Juan;
Zhang, Qian;
Jia, Hong;
Sun, Jianfang;
Lai, Yongxian

Publication type:

Article

Peroxisome Proliferator-Activated Receptor γ Agonist Rosiglitazone Protects Blood–Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway.

Published in:

Inflammation, 2019, v. 42, n. 3, p. 841, doi. 10.1007/s10753-018-0940-2

By:

Zhao, Yonglin;
Wei, Xing;
Song, Jinning;
Zhang, Ming;
Huang, Tingqin;
Qin, Jie

Publication type:

Article

Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.

Published in:

Inflammation, 2015, v. 38, n. 6, p. 2105, doi. 10.1007/s10753-015-0193-2

By:

Zhang, Yun-Fang;
Zou, Xun-Liang;
WU, Jun;
Yu, Xue-Qing;
Yang, Xiao

Publication type:

Article